InDex Pharmaceuticals Holding AB (publ) interim report January – September 2020
Phase III plan laid out“We have now laid out our plan for the phase III program with cobitolimod, which will form the basis for market approval, and we intend to finance the important initial induction study through a fully guaranteed rights issue of approximately SEK 500 million. In collaboration with the leading experts in the field we have arrived at a design that in an efficient manner will provide the basis to be able to draw firm conclusions regarding cobitolimod’s efficacy and safety as well as solid ground for a successful future commercialisation,” says Peter Zerhouni, CEO of InDex